Last update Nov. 23, 2023
Decreased level of risk
New scientific evidences have driven the Apilam staff to update the level of risk associated to this product.
Former level of risk, which was Possibly safe. Probably compatible. Mild risk possible. Follow up recommended. Read the Comment., is now set to Safe. Compatible. Minimal risk for breastfeeding and infant.
Level of risk reviewed on Nov. 23, 2023
Very Low Risk
Lemborexant is a dual orexin receptor antagonist used to treat insomnia in adults. Oral administration in one dose at bedtime.
At the date of the last update we did not find any published data on its excretion in breast milk.
Its pharmacokinetic data (high percentage of binding to plasma proteins, very large volume of distribution and moderately high molecular weight) explain the minimal passage into breast milk observed. (Rawal 2023, Saito 2023)
Infants exposed to this drug through breast milk should be monitored for excessive sedation and/or poor feeding. (FDA 2019)
Due to its sedative effect, it is not recommended to share a bed with the baby if this drug is being taken. (UNICEF 2018, 2017, 2014 and 2013, Landa 2012, ABM 2008, UNICEF 2006)
Suggestions made at e-lactancia are done by APILAM team of health professionals, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it. The pharmaceutical industry contraindicates breastfeeding, mistakenly and without scientific reasons, in most of the drug data sheets.
Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.
Thank you for helping to protect and promote breastfeeding.
e-lactancia is a resource recommended by Academy of Breastfeeding Medicine - 2006 of United States of America
Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM